 SOUTH SAN FRANCISCO, Calif., Jan. 25, 2021 GLOBE NEWSWIRE -- CareDx, Inc. Nasdaq: CDNA, a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the closing of its previously announced public offering of 1,923,077 shares of its common stock at a public offering price of 91.00 per share. In addition, CareDx has granted the underwriters a 30-day option to purchase up to 288,461 additional shares of its common stock. The net proceeds to CareDx from the offering are expected to be approximately 164.0 million, after deducting underwriting discounts and commissions and estimated offering expenses. 